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Although polyneuropathies associated with IgM and IgG monoclonal gam- 
mopathies have been well described, polyneuropathy with IgA monoclonal 
gammopathy of undetermined significance (MGUS) is less commonly seen 
and has not been well studied. We reviewed the clinical and electrodiag- 
nostic features of 5 such patients, and the sural nerve biopsy findings in 4 
of them. One patient was diabetic, while 4 were free of other diagnoses 
commonly associated with neuropathy. Clinical presentations were varied. 
Electrodiagnostic and histological studies ranged from primary demyelina- 
tion to primary axon loss to a mixed axonaVdemyelinating picture. Three 
patients who were treated appeared to respond to prednisone or intrave- 
nous gamma globulin, despite clear clinical, electrodiagnostic, and histolog- 
ical differences. We conclude that the polyneuropathy associated with IgA 
MGUS is heterogeneous, similar to that in IgM and IgG MGUS. A trial of 
immunomodulating therapy appears to be warranted in such patients if the 
neuropathy is sufficiently severe. 0 1993 John Wiley & Sons, Inc. 
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polyneuropathies associated with monoclonal 
gammopathies are of interest because of the 
potential relationship between the monoclonal 
protein and immune-mediated nerve damage. 
Clues to pathophysiologic mechanisms may come 
from clinical presentations and electrodiagnostic 
studies. Many patients have been described in 
whom polyneuropathy is associated with I M or 
While some such patients have gammopathies of 
undetermined significance, others have a variety 
of malignant plasma cell dyscrasias. The associ- 
ated polyneuropathies are clinically, electrodiag- 
nostically, and histologically heterogeneous; some 
IgG monoclonal gammopathy. 9,10.15,16,19-2~,2.5-29 
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exhibit primarily axonal features, while others pri- 
marily show demyelination. In contrast, descrip- 
tions of patients with polyneuropathy and IgA 
monoclonal gammopathy- particularly IgA mon- 
oclonal gammopathy of undetermined significance 
(MGUS)-are rare. In an attempt to describe such 
patients more completely, we have reviewed clini- 
cal, electrodiagnostic, and sural nerve biopsy data 
on a group of such patients seen at our institution. 
MATERIALS AND METHODS 
All patients seen at the University of Michigan 
Neuromuscular Clinic in the past 5 years who had 
both a polyneuropathy and an IgA monoclonal 
gammopathy were identified, and detailed chart 
reviews were performed. One patient (patient 5) 
had diabetes mellitus. No patients had systemic 
cancer, a history of excessive alcohol use, or other 
disorders (except for diabetes) known to cause 
neuropathy. All had undergone a comprehensive 
evaluation to rule out other causes of neuropathy, 
including physical examination, complete blood 
count, Westegren sedimentation rate, glucose, gly- 
cosylated hemoglobin, glucose tolerance test, elec- 
trolytes, BUN, creatinine, liver function tests, thy- 
roid function tests, vitamin BI2 level, VDRL, and 
chest X-ray. Monoclonal gammopathies were de- 
tected by high-resolution agarose gel serum elec- 
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Table 1. Patient population and immunological features 
Patient Age (y) Sex Light chain Serum IgA level (mg/dL)* Urine immunoelectrophoresis Other disease 
1 42 F Lambda 
2 41 M Lambda 
4 70 M Lambda 
5 44 M Lambda 








Kappa light chains 
Normal 








'Normal = 24-386 mgidl 
trophoresis, immunoglobulin quantification, de- 
termination of kappa-to-lambda light chain ratio 
and, if necessary, immunofixation. l8 Malignant 
plasma cell dyscrasias were excluded by normal 
bone marrow biopsies and radiologic skeletal sur- 
veys. 
Nerve conduction studies and needle electro- 
myography had been performed on all patients. 
Motor and antidromic sensory nerve conduction 
studies were performed using standard techniques 
of supramaximal percutaneous stimulation and 
surface electrode recording, maintaining skin tem- 
perature 2 32"C, as previously described.' Needle 
electromyography recordings were performed us- 
ing standard concentric needle electrodes. 
Sural nerve biopsies, received fresh and 
stretched by adhesion to a piece of cardboard, 
were divided into three portions. One portion was 
fixed in 10% formalin, embedded in paraffin, and 
stained with hematoxylin and eosin, Masson tri- 
chrome, and Congo red for light microscopy. A 
second portion was fixed in Karnowski mixture 
(2.5% glutaraldehyde, 3% formalin) and postfixed 
in 1% osmium tetroxide; part of this was embed- 
ded in Epon for light and electron microscopy, 
while part was treated with glycerol, 70% and 
loo%, for teasing. The third portion of the nerve 
was frozen in liquid nitrogen and treated with 
fluorescein-conjugated goat antibodies against hu- 
man IgA, IgG, IgM, C3, C4, and kappa and 
lambda light chains for evaluation under fluores- 
cent light. 
Each teased fiber was graded by a neuro- 
pathologist as showing one of five patterns: (1) 
normal; (2) myelin irregularity (focal myelin thick- 
ening at the node of Ranvier or the internode); (3) 
segmental demyelination- remyelination; (4) ax- 
onal degeneration; or (5) axonal regeneration. 
The pathologist then generated an overall histo- 
logical impression of the neuropathy (demyelinat- 
ing vs. axonal vs. mixed) based on the predomi- 
nant finding from teased fiber analysis, in 
conjunction with Epon-embedded light and elec- 
tron microscopy results. 
RESULTS 
Of 50 patients seen in our Neuroniuscular Clinic 
with polyneuropathy and monoclonal or biclonal 
gammopathy of undetermined significance, 5 
(10%) had IgA MGUS. Demographic and immu- 
nological features are summarized in Table 1, 
while clinical features appear in Table 2. Serum 
Table 2. Clinical features 
Patient Clinical presentation 
Upper and lower limb 
strength* Sensory loss 
1 Painful upper and lower extremity paresthesias bilateral Upper P5/D5- Large and small fiber 
2 Painful distal upper and lower extremity paresthesias Upper P5/D5 Small fiber 
3 Back and right leg pain painful distal paresthesias Upper P5/D5 Large fiber 
4 Painful sensorimotor mononeuropathy multiplex Upper P5iD5 Large and small fiber 
5 Painful upper and lower extremity paresthesias with gait Upper P5/D5 Large and small fiber 




ataxia Lower PWD5 
'MRC scale P = proximal. D = distal 
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IgA levels varied from normal (patient 5) to mod- 
erately elevated (patient 3), with most patients 
having mildly elevated serum IgA levels. Urine 
irnmunoelectrophoresis was normal in 3 of the 5 
patients. Serum antibodies to myelin associated 
glycoprotein (MAG) were absent in patients 1 and 
3, and were not assessed in the other patients. 
'The polyneuropathy was discovered inciden- 
tally in patient 3, who presented for evaluation of 
back and leg pain, but who was found on exami- 
nation and electrodiagnostic studies to have a 
polyneuropathy. Shortly after initial evaluation, 
he developed painful, distal paresthesias. All other 
patients presented with complaints of pain, sen- 
sory loss, weakness, or a combination of these. 
Neurological examination (Table 2) revealed 
weakness which was predominantly distal in 2 pa- 
tiients, while strength was normal in the others. 
Sensory loss was present in all. Only patient 1 had 
total areflexia, though Achilles reflexes were ab- 
slent in patients 3 and 4. 
Electrodiagnostic data for several representa- 
twe nerves is summarized in Table 3. Patient 1 was 
felt to have a primary demyelinating polyneuropa- 
thy, and was the only subject whose EMG met for- 
mal electrodiagnostic criteria' for chronic inflam- 
matory demyelinating polyneuropathy (CIDP). 
Patients 2 and 3 had electrodiagnostically mild 
polyneuropathies, with few to no abnormalities on 
needle examination. The EMG on patient 4 showed 
asymmetric denervation, compatible with a monon- 
europathy multiplex. A polyradiculoneuropathy 
was present in patient 5, with prominent paraspinal 
muscle and distal limb muscle denervation. The 
findings in patients 1, 2, 3, and 5 were symmetric. 
Sural nerve biopsies were performed on pa- 
tients 2-5.  Heterogeneity was clearly present, al- 
though most of the biopsies showed a mixed ax- 
onal and demyelinating picture. No widening of 
the myelin lamellae of the type seen in some IgM- 
associated neuropathies* ',*' was noted. Teased fi- 
ber data as well as the overall impression from 
both light and electron microscopy are provided 
in Table 4. While the biopsy of patient 4 did show 
perivascular mononuclear infiltrates around small 
epineurial blood vessels, a clear necrotizing vascu- 
litis was not present. Immunofluorescence studies 
of patients 2, 3, and 4 revealed slight, diffuse 
Table 3. Electrodiagnostic studies 
Patient number 
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>40 
<3.5 
Amp- amplitude (mV); DL. distal latency (ms); CV: conduction velocity (mis), F /at: F-wave latency (ms); PiD: proximalidistal amplitude ratio; ND: not 
done; NR: no response. 
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Table 4. Sural nerve biopsy results. 
Teased fiber classification (% of fibers) 
Segmental 
No of demyelination- Axonal Axonal tiistological impression 
Pt fibers teased Myelin irregularity* remyelination degeneration regeneration of neuropathy 
2 72 7 
3 65 <2 
4 67 0 
5 80 12 
14 4 3 Mixed, demyelinating > axonal 
9 5  0 20 Mixed, axonal > demyelinating 
4 24 15 Axonal with minimal 
8 75 3 75 25 Mixed, demyelinating 2 axonal 
demyelination 
'Focal myelin thickening at the node of Ranvier or the internode 
staining of the endoneurium and perineurium, in- 
terpreted as nonspecific since such staining was 
also seen in control nerves. There was no selective 
IgC, IgM, or Ig,4 binding to the myelin sheath. 
Three patients (patients 1, 3 ,  and 4) were 
treated. Initial therapy in all consisted of pred- 
nisone 60 mg/;ltl, ivhich was gradually tapered. Pa- 
tient l experienced a mild increase in strength 
with prednisone, then improved further with 
monthly intravenous gamma globulin infusions. 
After 1.5 years, she had only mild ankle dorsi- 
flexor weakness (MRC grade 4+). Patient 3 had 
pain but no weakness at onset. Treatment resulted 
in a gradual resolution of the pain over the next 4 
months, with an increase in functional capacity. 
Patient 4, whose main neurological deficit was dis- 
tal lower extremity weakness, had some increased 
strength (by one MRC grade) in that muscle 
group over thc first 2 months of treatment, but 
then died as a result of his underlying pulmonary 
disease. Of the untreated patients, patient 2 was 
lost to follow-up after his diagnostic evaluation, 
and patient 5 had only sensory symptoms, which 
were not felt to be sufficiently disabling to warrant 
the use of prednisone in light of his diabetes. 
DISCUSSION 
Patients with polyneuropathy and IgM or IgG 
monoclonal gammopathy are clinically, electro- 
diagnostically, and histologically heterogene- 
presumably secondary to 
more than one mechanism of nerve fiber damage; 
some have primarily demyelinating neuropathies, 
while in others the neuropathy shows mainly ax- 
onal features. 'I'he best studied are those with IgM 
monoclonal gammopathy. Among these patients, 
those with elevated titers of antibodies to myelin- 
associated glycoprotein (MAG) are felt to form a 
relatively homogeneous group, presumably sec- 
ous,Y,lo,l 5 ,  Ih, I !1--22,2',-29 
ondary to a uniform mechanism of nerve dam- 
age. 
Polyneuropathy occurs less commonly in asso- 
ciation with IgA monoclonal gammopathy. Such 
patients constituted only 10 of 65 patients (15%) 
with polyneuropathy and MGUS in a recent Mayo 
Clinic review," and only 5 of 50 cases (10%) seen 
at our institution with polyneuropathy and mono- 
clonal or biclonal gamrnopathy of undetermined 
significance. This is roughly comparable with the 
12% prevalence of IgA monoclonal gammopathies 
out of 7004 total patients with MGUS seen over a 
27-year period at the Mayo Clinic." Many of the 
cases of polyneuropathy and IgA MGUS de- 
scribed in the literature have had lambda light 
chains and osteosclerotic That sub- 
group is relatively homogeneous, typically resem- 
bling CIDP, with motor greater than sensory 
involvement, elevated cerebrospinal fluid pro- 
tein levels, and electrodiagnostic studies showing 
slowed conduction velocities, increased distal la- 
tencies, and abnormal temporal dispersion/con- 
duction block. 
In contrast, patients with IgA monoclonal 
gammopathy and peripheral nervous system dis- 
ease without osteosclerotic myeloma have been 
varied. Excluding those reported patients who ap- 
pear to have motor neuron disease, those with ma- 
lignant plasma cell dyscrasias, and those with os- 
teosclerotic myeloma, there are 6 patients with 
polyneuropathy in whom the monoclonal gam- 
mopathy is of Undetermined significance and who 
have been well described. Three are single 
cases,324914 while the other 3 constitute a small se- 
ries of patients.23 The clinical characteristics, pri- 
mary mechanism of nerve damage, and immuno- 
logical .staining in these 6 patients and our 5 
additional patients are summarized in Table 5. 
As can be seen, 3 of the previously described 
13,15,16,25,'L8 
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Table 5. Summary of patients with polyneuropathy and IgA monoclonal gammopathy of undetermined significance. 
Light Duration of Main clinical Neuropathy type- 
Reference chain symptoms feature* studiest 
Immunological 
studies* 
Nemni et al ,23 
case 1 
Nemni e l  aLY3 
case 2 
N'ernni et al ,23 
case 3 
Baily et aL3 







Kappa l Y  S only Ax-edx Polyclonal IgG staining of 
Lambda 2Y M >> S Dem(?)-edx Polyclonal IgG staining of 
Kappa 2OY S, M, A D e m - e d x IgA kappa staining of 
Not reported Hernachudha 
et ai,14 






M > S  
Dem-edx and bx 
Ax-edx and bx Diffuse IgG staining of 
endoneurium, 
subperineurial space 











Mixed dem > ax-bx Mild, diffuse IgM, IgG, 
and IgA staining of 
perineuriurn and 
endoneurium 
Mild, diffuse IgM, IgG, 
and IgA staining of 
perineunum and 
endoneurium 
Mild. diffuse IgM, IgG, 
and IgA staining of 
penneuriurn and 
endoneurium 
S only Mixed dem 2 ax-bx Not done 
This report, 
case 3 
a mo S only Mixed ax > dern-bx 
This report, 
case 4 
Lambda 3Y Ax-edx and bx 
Lambda 2Y Tliis report, 
case 5 
*Akin clinical feature of neuropathy: M = motor, S = sensory, A = autonomic 
tldeuropathy type-studies: type of neuropathy and means of determination. ax = axonal, dern = demyelinating, edx = electrodiagnostic studies, bx = 
sural nerve biopsy. 
#immunological studies = imrnunoperoxidase or immunofluorescence staining of sural nerve. 
Only 2 of the patients described previously 
were treated. One,' who had serum antibodies to 
myelin-associated glycoprotein, improved dramat- 
ically with prednisone. The other4 did not re- 
spond to plasma exchange, prednisone, or other 
immunosuppression. Patients with polyneuropa- 
thy and IgM or IgG MGUS have improved after 
treatment with a variety of immunosuppressive 
agents, including prednisone, chlorambucil, aza- 
thioprine, cyclophosphamide, plasma exchange, 
and intravenous gamma g l o b ~ l i n . ~ - ' ~ ~ ~ ' ~ ~ ' ~  In the 
absence of clear data favoring one specific thera- 
peutic modality, we decided to treat initially with 
prednisone, and later used gamma globulin in 1 
patient. Although our 3 treated patients all ap- 
peared to respond favorably, conclusions regard- 
ing treatment are limited in our small series; while 
1 patient clearly improved with prednisone and 
gamma globulin, 1 patient's improvement was lim- 
patients have had kappa light chains, while 3 have 
hLad lambda. Clinical presentations have varied 
greatly. Three have shown predominantly demy- 
elinating features by electrodiagnostic studies or 
bliopsy, while 3 appear to be primarily axonal. The 
clinical features and the primary mechanism of 
nerve damage did not correspond to the type of 
light chain present. None of the patients in whom 
iimmunological staining was performed showed 
IgA lambda or IgA kappa staining of a specific pe- 
ripheral nerve component. Similarly, our 5 pa- 
tients had both lambda and kappa light chains, 
and exhibited a variety of clinical, electrodiagnos- 
tic, and histological features. Thus, patients with 
polyneuropathy and IgA MGUS appear to be het- 
erogeneous, similar to the more commonly seen 
patients with IgG and IgM MGUS. As with those 
patients, this most likely reflects a variety of mech- 
anisms of nerve damage. 
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ited to the resolution of paresthesias, and another 
patient died 2 months into therapy after begin- 
ning to show some improved strength. The neu- 
ropathy was predominantly demyelinating in one 
of these patients and predominantly axonal in the 
other two. This is in agreement with previous re- 
ports that patients with either demyelinating or 
axonal polyneuropathies and IgM or IgG mono- 
clonal gammo athies have responded favorably to 
Because of the suggestion 
that imniunornodulatirig therapy may be effective, 
the nature of the nerve injury should not exclude 
a trial of such therapy in these patients, at least 
until more definitive information on treatment is 
available. 
We are unable to clarify the causal relationship, 
if any, between the monoclonal gammopathy and 
the polyneuropathy in these atients. This to ic has 
A causal relationship is considered likely in patients 
with IgM MGUS and antibodies to MAG, but has 
not been unequivocally proven. Several factors ar- 
gue against a direct causal role for the IgA MGUS 
in our patients: (1) the comparable prevalence of 
IgA heavy chain in patients with MGUS with and 
without polyneuropathy ; (2) the presence of a poly- 
radiculoneuropathy in our diabetic patient (patient 
5), which was indistinguishable from diabetic poly- 
radiculoneuropathy ; and (3) the lack of selective 
IgA binding t o  specific nerve components. Thus, 
the MGUS mav be coincidental in our patients, or 
may simply be an indicator of an underlying au- 
toimmune process. While the apparent response of 
some of our patients to immunomodulating ther- 
apy would support an autoimmune pathogenesis, 
the process presumably may be directed against a 
variety of peripheral nerve antigens, given the het- 
erogeneity of clinical, electrodiagnostic, and histo- 
logical presentations. 
..5,<). I r.1 f i .24,2fi,2i 
been extensively discussed. L, 16 , lY~20 ,22 ,24 ,25~~ .30 ,3  1 
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